Bill > S1250

This bill, called the "Drug-price Transparency for Consumers Act of 2023" or the "DTC Act of 2023," would require direct-to-consumer advertisements for drugs and biologicals covered by Medicare or Medicaid to include the wholesale acquisition cost (WAC), which is the list price set by the manufacturer, for a 30-day supply or typical course of treatment. The requirement would not apply to drugs with a WAC of less than $35 for a 30-day supply. The bill aims to improve transparency and allow consumers to make more informed decisions about their medication purchases, especially for those with high-deductible health plans or Medicare coverage that exposes them to the full list price. The Secretary of Health and Human Services would have one year to issue regulations to implement the pricing disclosure requirement and establish enforcement mechanisms, including potential civil monetary penalties for non-compliance.